PMID- 36009431
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 8
DP  - 2022 Aug 4
TI  - Differential Effects of Anti-TNFalpha and Anti-alpha4beta7 Drugs on Circulating Dendritic 
      Cells Migratory Capacity in Inflammatory Bowel Disease.
LID - 10.3390/biomedicines10081885 [doi]
LID - 1885
AB  - Inflammatory bowel disease (IBD) is an idiopathic and chronic disorder that 
      includes ulcerative colitis (UC) and Crohn's disease (CD). Both diseases show an 
      uncontrolled intestinal immune response that generates tissue inflammation. 
      Dendritic cells (DCs) are antigen-presenting cells that play a key role in 
      tolerance maintenance in the gastrointestinal mucosa. Although it has been 
      reported that DC recruitment by the intestinal mucosa is more prominent in IBD 
      patients, the specific mechanisms governing this migration are currently unknown. 
      In this study, the expression of several homing markers and the migratory profile 
      of circulating DC subsets towards intestinal chemo-attractants were evaluated and 
      the effect of biological drugs with different mechanisms of action, such as 
      anti-TNFalpha or anti-integrin alpha4beta7 (vedolizumab), on this mechanism in healthy 
      controls (HCs) and IBD patients was also assessed. Our results revealed that type 
      2 conventional DCs (cDC2) express differential homing marker profiles in UC and 
      CD patients compared to HCs. Indeed, integrin beta7 was differentially modulated by 
      vedolizumab in CD and UC. Additionally, although CCL2 displayed a 
      chemo-attractant effect over cDC2, while biological therapies did not modulate 
      the expression of the homing markers, we paradoxically found that 
      anti-TNF-treated cDC2 increased their migratory capacity towards CCL2 in HCs and 
      IBD. Our results therefore suggest a key role for cDC2 migration towards the 
      intestinal mucosa in IBD, something that could be explored in order to develop 
      novel diagnostic biomarkers or to unravel new immunomodulatory targets in IBD.
FAU - Soleto, Irene
AU  - Soleto I
AUID- ORCID: 0000-0002-8005-2411
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Fernandez-Tome, Samuel
AU  - Fernandez-Tome S
AUID- ORCID: 0000-0002-6893-4833
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
AD  - Departamento de Nutricion y Ciencia de los Alimentos, Facultad de Farmacia, 
      Universidad Complutense de Madrid, 28040 Madrid, Spain.
FAU - Mora-Gutierrez, Irene
AU  - Mora-Gutierrez I
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
AD  - Biobanco del Sistema de Salud de Aragon, 50009 Zaragoza, Spain.
FAU - Baldan-Martin, Montserrat
AU  - Baldan-Martin M
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Ramirez, Cristina
AU  - Ramirez C
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Santander, Cecilio
AU  - Santander C
AUID- ORCID: 0000-0001-5492-2535
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Moreno-Monteagudo, Jose Andres
AU  - Moreno-Monteagudo JA
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Casanova, Maria Jose
AU  - Casanova MJ
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Casals, Fernando
AU  - Casals F
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Casabona, Sergio
AU  - Casabona S
AUID- ORCID: 0000-0002-6131-8341
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Becerro, Irene
AU  - Becerro I
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Chaparro, Maria
AU  - Chaparro M
AUID- ORCID: 0000-0002-9275-4242
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
FAU - Bernardo, David
AU  - Bernardo D
AUID- ORCID: 0000-0002-2843-6696
AD  - Mucosal Immunology Lab, Centro de Investigaciones Biomedicas en Red de 
      Enfermedades Infecciosas (CIBERINFEC), Unidad de Excelencia Instituto de Biologia 
      y Genetica Molecular (IBGM), Universidad de Valladolid, 47005 Valladolid, Spain.
AD  - Centro de Investigacion Biomedica en Red de Enfermedadmes Infecciosas 
      (CIBERINFEC), 28029 Madrid, Spain.
FAU - Gisbert, Javier P
AU  - Gisbert JP
AUID- ORCID: 0000-0003-2090-3445
AD  - Gastroenterology Unit, Centro de Investigacion Biomedica en Red de Enfermedades 
      Hepaticas y Digestivas (CIBERehd), Hospital Universitario de La Princesa, 
      Instituto de Investigacion Sanitaria Princesa (IIS-Princesa), Universidad 
      Autonoma de Madrid (UAM), 28006 Madrid, Spain.
LA  - eng
GR  - CD17/00014/Instituto de Salud Carlos III/
GR  - CD21/00014/Instituto de Salud Carlos III/
GR  - Beca del Grupo Joven/Asociacion Espanola de Gastroenterologia/
GR  - CCVC8485/Instituto de Biologia y Genetica Molecular/
GR  - PID2019-104218RB-I00/Plan Nacional Spanish Government/
GR  - GIS-INH-2015/MSD spain/
GR  - GIS-INH-2015/Janssen Spain/
PT  - Journal Article
DEP - 20220804
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC9405461
OTO - NOTNLM
OT  - anti-TNFalpha
OT  - biological drugs
OT  - dendritic cells
OT  - inflammatory bowel disease
OT  - intestinal mucosa
OT  - migration
OT  - vedolizumab
COIS- Gisbert has served as speaker, consultant and advisory member for/or has received 
      research funding from MSD, Abbvie, Pfizer, Kern Pharma, Biogen, Mylan, Takeda, 
      Janssen, Roche, Sandoz, Celgene/Bristol Myers, Gilead/Galapagos, Lilly, Ferring, 
      Faes Farma, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Chiesi, 
      Casen Fleet, Gebro Pharma, Otsuka Pharmaceutical, Norgine and Vifor Pharma. Maria 
      Chaparro has served as a speaker and as consultant. She has received research 
      and/or education funding from MSD, Abbvie, Hospira, Pfizer, Takeda, Janssen, 
      Ferring, Shire Pharmaceuticals, Dr. Falk Pharma, Tillotts Pharma, Biogen, Gilead 
      and Lilly.
EDAT- 2022/08/27 06:00
MHDA- 2022/08/27 06:01
PMCR- 2022/08/04
CRDT- 2022/08/26 01:05
PHST- 2022/06/15 00:00 [received]
PHST- 2022/07/28 00:00 [revised]
PHST- 2022/08/02 00:00 [accepted]
PHST- 2022/08/26 01:05 [entrez]
PHST- 2022/08/27 06:00 [pubmed]
PHST- 2022/08/27 06:01 [medline]
PHST- 2022/08/04 00:00 [pmc-release]
AID - biomedicines10081885 [pii]
AID - biomedicines-10-01885 [pii]
AID - 10.3390/biomedicines10081885 [doi]
PST - epublish
SO  - Biomedicines. 2022 Aug 4;10(8):1885. doi: 10.3390/biomedicines10081885.